"I am just supposing that after the prostate assay is complete, other assays would follow in much less the time it took to develop the prostate."
Erthang,
Actually, Dr. Moro seems to have discussed that in your interview with him. He said "...That would take too long. So there is a much easier way to do it. I just want the approval for prostate, and while we get that, we give them the evidence for lung and then I apply for an extension of the application now for lung, and so on and so forth."
Perhaps Dr. Moro is talking here about getting "Substantially Equivalent" 510k FDA approvals after going though the first FDA PMA process. This is also what Abbott may do. And it makes good sense because the RECAF blood serum test is not specific to any kind of cancer. It can only give a high probability that cancer is present in the body somewhere. It appears that only one basic RECAF blood serum test needs to be perfected to run on an automated analyzer, such as Abbott's Architect system. Once such a test is perfected to do that, its reliability just needs to be proven to the FDA for each type cancer that the test will serve as an early detection cancer screening test. Using the FDA substantially equivalent 510k provision on subsequent approvals should drastically speed up the FDA approval process. Last Tuesday's press release gives proof that BioCurex's RECAF test can serve as a blood test for the early detection of breast cancer. Abbott has been working for over a year to implement a serum RECAF test into their Architect system. We just have to be getting very close to some news that will have money attached to it. Possibly a lot of money. kag
